Acute Antibody-Mediated Rejection in Renal Transplantation: Current Clinical Management

Acute antibody-mediated rejection (AMR) is recognized as a major cause of graft loss in renal transplant recipients. Early acute AMR in the first few days after transplantation occurs primarily in sensitized renal transplant recipients with donor-specific alloantibody at the time of transplant and is a relatively “pure” form of acute AMR. Late acute AMR occurs months to years after transplantation and is commonly a mixed cellular and humoral rejection. While there is no consensus regarding optimum treatment, we contend that rational therapeutic approaches are emerging and that the acute episode can be managed in most instances. However, new therapies are needed to prevent ongoing chronic injury in these patients.